Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics
European Pharmaceutical Review
FEBRUARY 1, 2024
In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.
Let's personalize your content